PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging

被引:51
|
作者
Irwin, Christopher P. [1 ]
Portorreal, Yasiri [1 ]
Brand, Christian [1 ]
Zhang, Yachao [1 ]
Desai, Pooja [1 ]
Salinas, Beatriz [1 ]
Weber, Wolfgang A. [2 ,3 ]
Reiner, Thomas [1 ,4 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Radiol, Radiochem & Imaging Sci Serv, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Radiol, Mol Imaging & Therapy Serv, New York, NY 10065 USA
[3] Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, New York, NY 10065 USA
[4] Mem Sloan Kettering Canc Ctr, Ctr Mol Imaging & Nanotechnol, New York, NY 10065 USA
来源
NEOPLASIA | 2014年 / 16卷 / 05期
关键词
RESECTION; SURVIVAL; GLIOMA; EXTENT; EXPRESSION; OLAPARIB; GUIDANCE; SURGERY;
D O I
10.1016/j.neo.2014.05.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
New intravital optical imaging technologies have revolutionized our understanding of mammalian biology and continue to evolve rapidly. However, there are only a limited number of imaging probes available to date. In this study, we investigated in mouse models of glioblastoma whether a fluorescent small molecule inhibitor of the DNA repair enzyme PARP1, PARPi-FL, can be used as an imaging agent to detect glioblastomas in vivo. We demonstrated that PARPi-FL has appropriate biophysical properties, low toxicity at concentrations used for imaging, high stability in vivo, and accumulates selectively in glioblastomas due to high PARP1 expression. Importantly, subcutaneous and orthotopic glioblastoma xenografts were imaged with high contrast clearly defining tumor tissue from normal surrounding tissue. This research represents a step toward exploring and developing PARPi-FL as an optical intraoperative imaging agent for PARP1 in the clinic.
引用
收藏
页码:432 / 440
页数:9
相关论文
共 37 条
  • [31] Triple Combinations of Histone Lysine Demethylase Inhibitors with PARP1 Inhibitor-Olaparib and Cisplatin Lead to Enhanced Cytotoxic Effects in Head and Neck Cancer Cells
    Dorna, Dawid
    Kleszcz, Robert
    Paluszczak, Jaroslaw
    BIOMEDICINES, 2024, 12 (06)
  • [32] The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
    Herencia-Ropero, Andrea
    Llop-Guevara, Alba
    Staniszewska, Anna D.
    Domenech-Vivo, Joanna
    Garcia-Galea, Eduardo
    Moles-Fernandez, Alejandro
    Pedretti, Flaminia
    Domenech, Heura
    Rodriguez, Olga
    Guzman, Marta
    Arenas, Enrique J.
    Verdaguer, Helena
    Calero-Nieto, Fernando J.
    Talbot, Sara
    Tobalina, Luis
    Leo, Elisabetta
    Lau, Alan
    Nuciforo, Paolo
    Dienstmann, Rodrigo
    Macarulla, Teresa
    Arribas, Joaquin
    Diez, Orland
    Gutierrez-Enriquez, Sara
    Forment, Josep V.
    O'Connor, Mark J.
    Albertella, Mark
    Balmana, Judith
    Serra, Violeta
    GENOME MEDICINE, 2024, 16 (01):
  • [33] PARP1 inhibitor (PJ34) improves the function of aging-induced endothelial progenitor cells by preserving intracellular NAD+ levels and increasing SIRT1 activity
    Zha, Siyuan
    Li, Zhen
    Cao, Qing
    Wang, Fei
    Liu, Fang
    STEM CELL RESEARCH & THERAPY, 2018, 9
  • [34] PJ34, a PARP1 inhibitor, attenuates acute allograft rejection after murine heart transplantation via regulating the CD4+ T lymphocyte response
    Chen, Xing
    Huang, Yajun
    Wang, Dashuai
    Dong, Nianguo
    Du, Xinling
    TRANSPLANT INTERNATIONAL, 2021, 34 (03) : 561 - 571
  • [35] Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials
    Luo, Jing
    Dai, Xinchi
    Hu, Hua
    Chen, Jie
    Zhao, Lujun
    Yang, Changyong
    Sun, Jifeng
    Zhang, Lianmin
    Wang, Qian
    Xu, Shilei
    Xu, Yue
    Liu, Ningbo
    Ying, Guoguang
    Wang, Ping
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (03) : 721 - 737
  • [36] Temozolomide and the PARP Inhibitor Niraparib Enhance Expression of Natural Killer Group 2D Ligand ULBP1 and Gamma-Delta T Cell Cytotoxicity in Glioblastoma
    Jones, Amber B.
    Tuy, Kaysaw
    Hawkins, Cyntanna C.
    Quinn, Colin H.
    Saad, Joelle
    Gary, Sam E.
    Beierle, Elizabeth A.
    Ding, Lei
    Rochlin, Kate M.
    Lamb, Lawrence S.
    Hjelmeland, Anita B.
    CANCERS, 2024, 16 (16)
  • [37] CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer
    Xie, Xiao-Feng
    Wu, Nan-Qiang
    Wu, Jin-Feng
    Zhang, Guang-Lin
    Guo, Jin-Feng
    Chen, Xue-Lian
    Du, Cai-Wen
    CANCER LETTERS, 2022, 551